Jean-Luc Balligand, Dulce Brito, Oana Brosteanu, Barbara Casadei, Christophe Depoix, Frank Edelmann, Vanessa Ferreira, Gerasimos Filippatos, Bernhard Gerber, Damien Gruson, Dirk Hasenclever, Kristian Hellenkamp, Ignatios Ikonomidis, Bartosz Krakowiak, Renaud Lhommel, Masliza Mahmod, Stefan Neubauer, Alexandre Persu, Stefan Piechnik, Burkert Pieske, Elisabeth Pieske-Kraigher, Fausto Pinto, Piotr Ponikowski, Michele Senni, Jean-Noël Trochu, Nancy Van Overstraeten, Rolf Wachter, Anne-Catherine Pouleur
IMPORTANCE: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. OBJECTIVE: To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF...
September 20, 2023: JAMA Cardiology